n n n ‘.concat(e.i18n.t(“search.voice.recognition_retry”),’n
VANCOUVER, BC, Dec. 15, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), an intellectual fitness care company that promotes behavioral fitness classic and cutting-edge treatments. With a focus on safe, evidence-based psychedelic therapies, is proud to announce that its study site, Cedar Clinical Research (CCR), has been chosen as one of multiple sites for the phase-in clinical trial. 2b from Beckley Psytech for the treatment of resistant depression (DRT).
The study aims to evaluate the efficacy and safety of different doses of Beckley Psytech’s proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) – known as BPL-003 – as a potential therapy for TRD. It follows Beckley Psytech’s receipt of the U.S. Food and Drug Administration’s (FDA) first-ever Investigational New Drug (IND) approval for a Phase 2b study of a short-acting psychedelic compound in February this year. CCR’s selection as a clinical research site for this trial further establishes it as a leader in psychedelic clinical research and builds upon its commitment to forging collaborations that explore new mental health solutions.
“We are pleased to assist Beckley Psytech in its clinical trial efforts. These partnerships not only reflect the CCR’s commitment to overcoming barriers to intellectual aptitude studies; they also highlight our world-class features and infrastructure that position us as a highly sought-after clinical trial center,” said Dr. Paul Thielking, Chief Scientific Officer of Numinus. “Our collaboration with Beckley Psytech highlights a shared vision and commitment to applying the highest study criteria to psychedelic clinical trials. With each cutting-edge project, we further cement our global position, driven by innovation, integrity and excellence.
Numinus and CCR’s collaboration with Beckley Psytech reflects a unified drive for innovation in psychedelic-assisted therapies. As leaders in mental health solutions, they eagerly anticipate the transformative insights this Phase 2b trial will offer to the broader medical community.
Numinus and CCR remain at the forefront of psychedelic-assisted therapies, underscoring a deep commitment to studies that pave the way for a comprehensive cure. Click this link on Beckley Psytech to learn more about the study.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) is helping others heal and feel smart through progression and delivery of cutting-edge intellectual health care and access to safe, evidence-based psychedelic treatments. The Numinus style, which combines psychedelic studies and clinical care, is at the forefront of a transformation aimed at curing the symptoms of depression, anxiety, trauma, pain, and substance use rather than treating them. At Numinus, we are leading the integration of psychedelic-assisted treatments into mainstream clinical practice and building the foundation for a fitter society.
Learn more about www. numinus. com and us on LinkedIn, Facebook, Twitter, and Instagram.
About Beckley Psychotech
Beckley Psytech Ltd is a privately held clinical-stage biotechnology company committed to improving the lives of people with neuropsychiatric disorders by turning psychedelics into effective and legal medicines. Founded in 2019 and subsidized through more than two decades of pioneering clinical studies from the Beckley Foundation, Beckley Psytech combines state-of-the-art psychedelic science with extensive drug progression expertise to optimize patient outcomes, improve cure opportunities, and ease the burden of neuropsychiatric disease. Individuals, fitness systems, and society.
Forward-looking statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event “may”, “will”, “should”, “could” or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including but not limited to the challenges and uncertainties inherent in product and/or treatment development and in the psychedelics industry generally, availably of suitable subjects, the uncertainties of clinical success, possibility of adverse events, ability to meet project timelines and/or protocol requirements, and the risks set forth in the Company’s annual information form dated November 29, 2023, and available on SEDAR+ at www.sedarplus.com. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
View content to download media: https://www. prnewswire. com/news-releases/cedar-clinical-research-selected-as-clinical-research-site-for-beckley-psytechs-phase-2b-study-302016865Arrayhtml
SOURCE Numinus Wellness Inc.